Good evening :)
Place Order
Add to Watchlist

Apollo Hospitals Enterprise Ltd

APOLLOHOSP Share Price

7,159.500.25% (+17.50)

APOLLOHOSP Share Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CareHospitals & Diagnostic Centres
LargecapWith a market cap of ₹1,02,691 cr, stock is ranked 89
Low RiskStock is 1.44x as volatile as Nifty

How to use scorecard? Learn more

Health CareHospitals & Diagnostic Centres
LargecapWith a market cap of ₹1,02,691 cr, stock is ranked 89
Low RiskStock is 1.44x as volatile as Nifty

APOLLOHOSP Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
78.3814.030.22%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
50.616.440.53%

APOLLOHOSP Analyst Ratings & Forecast

Detailed Forecast 
86%
Analysts have suggested that investors can buy this stock

from 29 analysts

Price Upside

Earnings Growth

Rev. Growth

See Detailed Forecast

APOLLOHOSP Company Profile

Apollo Hospitals Enterprise Limited is a healthcare provider. The Company is engaged in offering healthcare services and operating standalone pharmacies.

Investor Presentation

View older 

Feb 10, 2025

PDF
View Older Presentations

APOLLOHOSP Similar Stocks (Peers)

Compare with peers 
PE Ratio
103.83
1Y Return
36.67%
Buy Reco %
75.00
PE Ratio
85.30
1Y Return
48.53%
Buy Reco %
100.00
PE Ratio
46.33
1Y Return
42.31%
Buy Reco %
66.67
PE Ratio
92.84
1Y Return
13.93%
Buy Reco %
71.43
PE Ratio
89.19
1Y Return
64.59%
Buy Reco %
92.31
Compare with Peers
APOLLOHOSP Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly

APOLLOHOSP Stock Summary · February 2025

The company demonstrated robust mid-teen revenue growth across all segments, driven by high-end specialties such as Cardiac Sciences and Oncology, while successfully optimizing its payer mix. Despite facing challenges from external market pressures, including a decline in inpatient volumes, management remains optimistic about future profitability, particularly through strategic expansions and digital initiatives. Operational efficiencies have improved margins, with a focus on enhancing occupancy rates and reducing the average length of stay. The integration of insurance services is expected to bolster revenue and improve margins, while ongoing projects aim to operationalize new facilities that will contribute significantly to growth. Overall, the company is strategically positioned to capitalize on emerging market opportunities while maintaining a commitment to sustainable profitability.

Key Points on Apollohosp Stock
APOLLOHOSP Stock Growth Drivers
8
  • Strong Financial Performance

    The company reported a robust financial performance in Q3 FY25, achieving mid-teen revenue growth across

  • Expansion of High-End Specialties

    The company has strategically focused on high-end specialties such as Cardiac Sciences, Oncology, and Neurosciences,

APOLLOHOSP Stock Challenges
5
  • Flat Growth in Key Segments

    The Outpatient and Inpatient businesses have experienced flat growth this quarter, leading to a revised

  • Challenges in Online Pharmacy Business

    Concerns have been raised regarding the financial struggles of the Online Pharmacy business, particularly in

APOLLOHOSP Forecasts

Price

Revenue

Earnings

APOLLOHOSP

Income

Balance Sheet

Cash Flow

APOLLOHOSP Income Statement

Industry refers to the sub-sector this company belongs to.
Higher than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 14.71%, vs industry avg of 10.01%

Increasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 26.28% to 30.13%

Lower than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 30.66%, vs industry avg of 42.91%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue6,286.927,320.588,275.859,648.9011,472.1010,665.6015,034.9016,702.8019,167.4021,344.10
Raw Materialssubtract3,135.333,646.224,110.854,732.505,605.905,809.407,646.808,598.809,839.0018,253.10
Power & Fuel Costsubtract122.80127.89166.68183.80213.00169.70193.70217.50247.20
Employee Costsubtract1,023.561,196.501,404.391,598.201,852.901,601.001,786.502,176.702,493.70
Selling & Administrative Expensessubtract976.591,169.011,432.571,125.60904.00624.80987.301,464.301,675.10
Operating & Other expensessubtract252.66387.50335.80913.701,083.801,217.701,863.202,105.602,413.50
Depreciation/Amortizationsubtract263.83314.04359.03395.50619.70573.10600.70615.40687.00736.20
Interest & Other Itemssubtract180.02257.35295.07327.00532.80449.20378.60380.80449.40463.00
Taxes & Other Itemssubtract95.751.0954.05136.60205.1070.30522.50324.60463.90581.70
EPS16.9915.888.4416.9632.7010.6373.4256.9762.5091.12
DPS6.006.005.006.006.003.0011.7515.0016.0016.00
Payout ratio0.350.380.590.350.180.280.160.260.260.18

APOLLOHOSP Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2018

Annual Report Unavailable

FY 2022

Annual report

PDF

Investor Presentation

May 26PDF
Nov 13PDF
Aug 14PDF
FY 2023

Annual report

PDF

Investor Presentation

May 30PDF
Feb 14PDF
Nov 11PDF
Aug 12PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 11PDF
FY 2025

Annual Report Pending

Investor Presentation

Feb 10PDF
Nov 6PDF
 

APOLLOHOSP Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CareHospitals & Diagnostic Centres

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Apollo Hospitals Enterprise Ltd114.2814.030.22%
Max Healthcare Institute Ltd103.8313.060.13%
Fortis Healthcare Ltd85.305.970.15%
Narayana Hrudayalaya Ltd46.3312.680.22%

APOLLOHOSP Stock Price Comparison

Compare APOLLOHOSP with any stock or ETF
Compare APOLLOHOSP with any stock or ETF
APOLLOHOSP
Loading...

APOLLOHOSP Shareholdings

APOLLOHOSP Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

APOLLOHOSP Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Decreased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has decreased by 2.53%

Tickertape Separator

APOLLOHOSP Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding29.34%15.42%6.87%42.74%5.64%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

APOLLOHOSP Shareholding History

Dec '23MarJunSepDec '24Mar46.25%45.63%43.92%45.37%45.27%42.74%

Mutual Funds Invested in APOLLOHOSP

Increased Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 2.65%

Top 5 Mutual Funds holding Apollo Hospitals Enterprise Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
1.0470%1.54%-0.24%41/67 (-2)
0.4663%1.27%0.18%49/94 (+4)
0.4586%2.73%0.37%7/76 (+2)

Compare 3-month MF holding change on Screener

APOLLOHOSP Insider Trades & Bulk Stock Deals

Loading...

smallcases containing APOLLOHOSP stock

Looks like this stock is not in any smallcase yet.

APOLLOHOSP Events

APOLLOHOSP Dividend Trend

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.22%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹2.24 every year

Dividends

Corp. Actions

Announcements

Legal Orders

APOLLOHOSP Upcoming Dividends

No upcoming dividends are available

APOLLOHOSP Past Dividends

Cash Dividend

Ex DateEx DateFeb 14, 2025

Interim
Interim | Div/Share: ₹9.00

Dividend/Share

9.00

Ex DateEx Date

Feb 14, 2025

Cash Dividend

Ex DateEx DateAug 16, 2024

Final
Final | Div/Share: ₹10.00

Dividend/Share

10.00

Ex DateEx Date

Aug 16, 2024

Cash Dividend

Ex DateEx DateFeb 20, 2024

Interim
Interim | Div/Share: ₹6.00

Dividend/Share

6.00

Ex DateEx Date

Feb 20, 2024

Cash Dividend

Ex DateEx DateAug 18, 2023

Final
Final | Div/Share: ₹9.00

Dividend/Share

9.00

Ex DateEx Date

Aug 18, 2023

Cash Dividend

Ex DateEx DateFeb 24, 2023

Interim
Interim | Div/Share: ₹6.00

Dividend/Share

6.00

Ex DateEx Date

Feb 24, 2023

APOLLOHOSP Stock News & Opinions

Corporate
Board of Apollo Hospitals Enterprise recommends interim dividend

Apollo Hospitals Enterprise announced that the Board of Directors of the Company at its meeting held on 10 February 2025, inter alia, have recommended the interim dividend of Rs 9 per equity Share (i.e. 180%) , subject to the approval of the shareholders.Powered by Capital Market - Live

2 months agoCapital Market - Live
Earnings
Apollo Hospitals Enterprise consolidated net profit rises 51.77% in the December 2024 quarter

Net profit of Apollo Hospitals Enterprise rose 51.77% to Rs 372.30 crore in the quarter ended December 2024 as against Rs 245.30 crore during the previous quarter ended December 2023. Sales rose 13.94% to Rs 5526.90 crore in the quarter ended December 2024 as against Rs 4850.60 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales5526.904850.60 14 OPM %13.7812.65 - PBDT720.80530.30 36 PBT536.20363.30 48 NP372.30245.30 52 Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Apollo Hospitals Enterprise announces board meeting date

Apollo Hospitals Enterprise will hold a meeting of the Board of Directors of the Company on 10 February 2025.Powered by Capital Market - Live

3 months agoCapital Market - Live
Live Market Update
Sensex tumbles 761 pts; pharma shares under pressure

The domestic equity benchmarks continued to trade with major losses in early afternoon trade. The Nifty slipped below the 24,250 mark. Pharma shares slipped after advancing in the past two consecutive trading sessions. At 12:30 IST, the barometer index, the S&P BSE Sensex dropped 760.75 points or 0.95% to 79,617.20. The Nifty 50 index fell 260.55 points or 1.06% to 24,223.40. In the broader market, the S&P BSE Mid-Cap index fell 0.38% and the S&P BSE Small-Cap index added 0.05%. The market breadth was positive. On the BSE, 1,952 shares rose and 1,876 shares fell. A total of 137 shares were unchanged. Derivatives: The NSE's India VIX, a gauge of the market's expectation of volatility over the near term, added 2.52% to 15.24. The Nifty 28 November 2024 futures were trading at 24,308, at a premium of 84.6 points as compared with the spot at 24,223.40. The Nifty option chain for the 28 November 2024 expiry showed maximum Call OI of 32.2 lakh contracts at the 25,000 strike price. Maximum Put OI of 40.4 lakh contracts were seen at 23,000 strike price. Buzzing Index: The Nifty Pharma index fell 1.73% to 22,523.05. The index rose 0.61% for the past two trading session. Glenmark Pharmaceuticals (down 5.5%), Ajanta Pharma (down 4.29%), Aurobindo Pharma (down 2.8%), Gland Pharma (down 2.37%), Alkem Laboratories (down 2.24%), Sun Pharmaceuticals Industries (down 2.18%), Lupin (down 1.72%), Zydus Lifesciences (down 1.6%), Cipla (down 1.44%) and Torrent Pharmaceuticals (down 1.41%) slipped. On the other hand, Biocon (up 0.9%), Granules India (up 0.73%) advanced. Stocks in Spotlight : Apollo Hospitals Enterprise jumped 6.20% after the company reported 62.64% surge in consolidated net profit to Rs 378.8 crore in Q2 FY25 as against Rs 232.9 crore posted in Q2 FY24. Revenue from operations increased 15.31% year on year (YoY) to Rs 5,589.3 crore in the quarter ended 30 September 2024. Kirloskar Ferrous Industries slipped 1.84% after the company reported 4.93% decline in consolidated net profit to Rs 77.64 crore in Q2 FY25 as compared to Rs Rs 81.67 crore in Q2 FY24. TeamLease Services declined 5.22% after the company's consolidated net profit declined 28% to Rs 25 crore despite 8% increase in revenue from operations to Rs 2797 crore in Q2 FY25. Usha Martin added 2.15% after the company reported 5.38% rise in consolidated net profit to Rs 109.72 crore in Q2 FY25 as against Rs 104.11 crore posted in Q1 FY25. Revenue from operations added 7.84% to Rs 891.17 crore in Q2 FY25 as against Rs 826.37 crore posted in Q1 FY25.Powered by Capital Market - Live

5 months agoCapital Market - Live
Spotlight
Apollo Hospitals spurts after Q2 PAT climbs 63% YoY to Rs 379 cr

Revenue from operations increased 15.31% year on year (YoY) to Rs 5,589.3 crore in the quarter ended 30 September 2024. Profit before tax in second quarter of FY25 was at Rs 557.4 crore, up 47.07% from Rs 379 crore recorded in similar period last fiscal. The company's EBITDA grew by 30% YoY to Rs 816 crore in the September 2024 quarter. On segmental front, revenue from Healthcare Services was at Rs 2,920.4 crore (up 13.81% YoY), revenue from Digital Health & Pharmacy distribution was Rs 2,282.2 crore (up 17.31% YoY) and revenue from Retail Health & Diagnostics stood at Rs 403.9 crore (up 14.03% YoY) during the quarter. As on 30 September 2024, Apollo Hospitals had 7,994 operating beds across the network (excluding AHLL & managed beds). The overall occupancy for hospitals was at 73% vs 68% in the same period in the previous year, aided by a strong increase in patient flows. On half year basis the company's consolidated net profit soared 71.21% to Rs 684 crore in H1 FY25 as against Rs 399.5 crore posted in H1 FY24. However the company's revenue from operation rose 15.22% YoY to Rs 10,674.9 crore in H1 FY25. Dr. Prathap C. Reddy, founder & chairman, Apollo Hospitals Group said, 'One of our proudest achievements is our recent partnership with the Government of Tripura to provide free heart surgeries for children, underscoring our belief that healthcare should reach those who need it most, especially in underserved communities. Beyond expanding access, we are advancing medical technology with innovative treatments like water vapor thermotherapy for prostate care and robotic radiosurgery systems for cancer. These state-of-the-art solutions make procedures less invasive and reduce recovery time, resulting in better patient outcomes. We're also investing in the future of healthcare with the launch of our new research academy, which is focused on driving groundbreaking medical discoveries that will shape the next generation of treatments. Our priorities remain clear-enhancing patient care, prioritizing safety, and advancing medical science. The first half of FY25 has been an exciting time for us, marked by these major milestones aimed at extending the reach and impact of our healthcare services. Moving forward, our mission is simple: to push the boundaries of healthcare and ensure that everyone, regardless of where they live, has access to the best medical services. This is our promise, and we are committed to making it a reality. Apollo Hospitals Enterprise is a private sector healthcare provider. It owns and operates hospitals across the country. Powered by Capital Market - Live

5 months agoCapital Market - Live
Spotlight
Stock Alert: Apollo Hospital Enterprise, Tata Steel, Power Grid Corporation of India, Sonata Software,

Result Today: Mahindra & Mahindra(M&M), Lupin, RVNL, Trent, Shyam Metalics, Indian Hotels, Goldiam International, Gujarat State Petronet, Gujarat Alkalies and Chemicals, Happy Forgings, HIL, Indigo Paints, ITD Cementation India, Jagran Prakashan, Kennametal India, Linde India, AAVAS Financiers, Abbott India, Akzo Nobel India, Alembic Pharmaceuticals, Bajaj Electricals, Carysil, Clean Science and Technology, Cummins India, Emami, Escorts Kubota, Great Eastern Shipping Co will declare their result later today Stocks to Watch: Apollo Hospitals Enterprise reported 62.64% surge in consolidated net profit to Rs 378.8 crore in Q2 FY25 as against Rs 232.9 crore posted in Q2 FY24. Revenue from operations increased 15.31% year on year (YoY) to Rs 5,589.3 crore in the quarter ended 30 September 2024. Tata Steel reported net loss of Rs 759 crore in Q2 FY25 as compared with net loss of Rs 6,511 crore in Q2 FY24. Revenue fell 3.2% YoY to Rs 53,905 crore during the quarter. Sonata Software's consolidated net profit increased marginally 0.8% to Rs 106 crore in Q2 FY25 as compared with Rs 105.6 crore in Q1 FY25. Revenue declined 14.13% QoQ to Rs 2,170 crore in Q2 FY25. Power Grid Corporation of India's consolidated net profit increased marginally 0.31% to Rs 3,793 crore in Q2 FY25 as compared with Rs 3,781 crore in Q2 FY24. Revenue rose slightly higher 0.08% to Rs 11,277 crore in Q2 FY25 as compared with Rs 11,267 crore in Q2 FY24. Pricol's consolidated net profit jumped 36.36% to Rs 45 crore on 15.74% increase in revenue to Rs 669 crore in Q2 FY25 over Q2 FY24. Delta Corp's consolidated net profit declined 60.86% to Rs 27 crore on 27.97% decline in revenue to Rs 188 crore in Q2 FY25 over Q2 FY24.Powered by Capital Market - Live

5 months agoCapital Market - Live
Spotlight
Apollo Hospitals Q2 PAT climbs 63% YoY to Rs 379 cr

Revenue from operations increased 15.31% year on year (YoY) to Rs 5,589.3 crore in the quarter ended 30 September 2024. Profit before tax in second quarter of FY25 was at Rs 557.4 crore, up 47.07% from Rs 379 crore recorded in similar period last fiscal. The company's EBITDA grew by 30% YoY to Rs 816 crore in the September 2024 quarter. On segmental front, revenue from Healthcare Services was at Rs 2,920.4 crore (up 13.81% YoY), revenue from Digital Health & Pharmacy distribution was Rs 2,282.2 crore (up 17.31% YoY) and revenue from Retail Health & Diagnostics stood at Rs 403.9 crore (up 14.03% YoY) during the quarter. As on 30 September 2024, Apollo Hospitals had 7,994 operating beds across the network (excluding AHLL & managed beds). The overall occupancy for hospitals was at 73% vs 68% in the same period in the previous year, aided by a strong increase in patient flows. On half year basis the company's consolidated net profit soared 71.21% to Rs 684 crore in H1 FY25 as against Rs 399.5 crore posted in H1 FY24. However the company's revenue from operation rose 15.22% YoY to Rs 10,674.9 crore in H1 FY25. Dr. Prathap C. Reddy, founder & chairman, Apollo Hospitals Group said, 'One of our proudest achievements is our recent partnership with the Government of Tripura to provide free heart surgeries for children, underscoring our belief that healthcare should reach those who need it most, especially in underserved communities. Beyond expanding access, we are advancing medical technology with innovative treatments like water vapor thermotherapy for prostate care and robotic radiosurgery systems for cancer. These state-of-the-art solutions make procedures less invasive and reduce recovery time, resulting in better patient outcomes. We're also investing in the future of healthcare with the launch of our new research academy, which is focused on driving groundbreaking medical discoveries that will shape the next generation of treatments. Our priorities remain clear-enhancing patient care, prioritizing safety, and advancing medical science. The first half of FY25 has been an exciting time for us, marked by these major milestones aimed at extending the reach and impact of our healthcare services. Moving forward, our mission is simple: to push the boundaries of healthcare and ensure that everyone, regardless of where they live, has access to the best medical services. This is our promise, and we are committed to making it a reality. Apollo Hospitals Enterprise is a private sector healthcare provider. It owns and operates hospitals across the country. The scrip added 0.05% to currently trade at Rs 6,974.70 on the BSE. Powered by Capital Market - Live

5 months agoCapital Market - Live
Earnings
Apollo Hospitals Enterprise consolidated net profit rises 62.64% in the September 2024 quarter

Net profit of Apollo Hospitals Enterprise rose 62.64% to Rs 378.80 crore in the quarter ended September 2024 as against Rs 232.90 crore during the previous quarter ended September 2023. Sales rose 15.32% to Rs 5589.30 crore in the quarter ended September 2024 as against Rs 4846.90 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales5589.304846.90 15 OPM %14.5912.95 - PBDT741.90540.50 37 PBT557.40377.10 48 NP378.80232.90 63 Powered by Capital Market - Live

5 months agoCapital Market - Live
Corporate
Apollo Hospitals Enterprise schedules board meeting

Apollo Hospitals Enterprise will hold a meeting of the Board of Directors of the Company on 6 November 2024.Powered by Capital Market - Live

6 months agoCapital Market - Live
Spotlight
Apollo Hospitals Q1 PAT surges 84% YoY to Rs 305 crore

Revenue from operations increased 15.12% year on year (YoY) to Rs 5,085.6 crore in the quarter ended 30 June 2024. Profit before tax in first quarter of FY25 was at Rs 430 crore, up 59.26% from Rs 270 crore recorded in similar period last fiscal. EBITDA grew by 32.63% to Rs 675.1 crore in the June 2024 quarter as against Rs 509 crore posted in Q1 FY25. EBITDA margin improved to 13.3% in Q1 FY25 as compared to 11.5% registered in the corresponding quarter previous year. During the quarter, the company's revenue from Healthcare Services was at Rs 2,637.3 crore (up 14.98% YoY) and revenue from Digital Health & Pharmacy distribution was Rs 2,082.1 crore (up 15.33% YoY) and the revenue from Retail Health & Diagnostics stood at Rs 366.1 crore (up 14.87% YoY). As on 30 June 2024, Apollo Hospitals had 7,942 operating beds across the network (excluding AHLL & managed beds). The overall occupancy for hospitals was at 68% vs 62% in the same period in the previous year, aided by a strong increase in patient flows across hospitals with inpatient (IP) volume increasing by 11% and outpatient (OP) new registrations by 13%. Dr. Prathap C. Reddy, chairman, Apollo Hospitals Group said, 'In the first quarter of FY25, we have seen significant growth and improved the reach of our retail operations. As we continue our growth journey, we remain dedicated to advancing healthcare excellence, implementing innovative solutions, and improving access to the best healthcare services throughout India and beyond.' Apollo Hospitals Enterprise is a private sector healthcare provider. It owns and operates hospitals across the country.' The scrip rose 0.82% to currently trade at Rs 6,640.35 on the BSE. Powered by Capital Market - Live

8 months agoCapital Market - Live

Frequently asked questions

  1. What is the share price of Apollo Hospitals Enterprise Ltd (APOLLOHOSP) today?

    The share price of APOLLOHOSP as on 24th April 2025 is ₹7159.50. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Apollo Hospitals Enterprise Ltd (APOLLOHOSP) share?

    The past returns of Apollo Hospitals Enterprise Ltd (APOLLOHOSP) share are
    • Past 1 week: 1.47%
    • Past 1 month: 7.35%
    • Past 3 months: 6.14%
    • Past 6 months: 2.95%
    • Past 1 year: 13.94%
    • Past 3 years: 48.73%
    • Past 5 years: 426.63%

  3. What are the peers or stocks similar to Apollo Hospitals Enterprise Ltd (APOLLOHOSP)?
  4. What is the dividend yield % of Apollo Hospitals Enterprise Ltd (APOLLOHOSP) share?

    The current dividend yield of Apollo Hospitals Enterprise Ltd (APOLLOHOSP) is 0.22.

  5. What is the market cap of Apollo Hospitals Enterprise Ltd (APOLLOHOSP) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Apollo Hospitals Enterprise Ltd (APOLLOHOSP) is ₹102691.00 Cr as of 24th April 2025.

  6. What is the 52 week high and low of Apollo Hospitals Enterprise Ltd (APOLLOHOSP) share?

    The 52-week high of Apollo Hospitals Enterprise Ltd (APOLLOHOSP) is ₹7545.35 and the 52-week low is ₹5693.20.

  7. What is the PE and PB ratio of Apollo Hospitals Enterprise Ltd (APOLLOHOSP) stock?

    The P/E (price-to-earnings) ratio of Apollo Hospitals Enterprise Ltd (APOLLOHOSP) is 114.28. The P/B (price-to-book) ratio is 14.03.

  8. Which sector does Apollo Hospitals Enterprise Ltd (APOLLOHOSP) belong to?

    Apollo Hospitals Enterprise Ltd (APOLLOHOSP) belongs to the Health Care sector & Hospitals & Diagnostic Centres sub-sector.

  9. How to buy Apollo Hospitals Enterprise Ltd (APOLLOHOSP) shares?

    You can directly buy Apollo Hospitals Enterprise Ltd (APOLLOHOSP) shares on Tickertape. Simply sign up, connect your demat account and place your order.